CD_4^+CD_(25)^+调节性T细胞在肿瘤免疫治疗中的价值及应用前景  

The Prospects of the usage of CD_4^+CD_(25)^+ regulatory T cells in cancer immunotherapy

作　　者：付泽娴[1] 蔡建辉[1] 

机构地区：[1]河北医科大学第二医院胃肠外科

出　　处：《中国全科医学》2005年第21期1799-1801,共3页Chinese General Practice

摘　　要：恶性肿瘤的临床治疗主要是手术治疗、化学治疗和放射治疗。近年来,随着分子生物技术的不断发展,肿瘤的生物治疗在临床应用中的地位日渐突出。但是免疫细胞过继治疗作用的一过性和功能抑制成为影响其临床应用的瓶颈,其中CD+4CD+25调节性T细胞(CD+4CD+25regulatoryTcell,Treg)在抑制肿瘤免疫方面起着重要作用。本文就其近年来的肿瘤临床研究进展做一综述。For the treatments of malignant tumors, the major therapies clinically used include operation, radiotherapy and chemotherapy. Recent years, with the development of the technologies of molecular biology, biotherapy is becoming more and more noticeable. However, the tumor adoptive immunotherapy is in a dilemma about the temporality and limited function of therapy effects. The CD4^＋CD25^＋ regulatory T cells （Treg） may play a key function in restraining tumor immunity. In this review, we summarized the new datum and approaches in the past few years about the usage of CD4^＋CD25^＋ Treg cells in cancer immunotherapy clinically.

关 键 词：肿瘤 CD4^+CD25^+调节性T细胞 免疫治疗 

分 类 号：R73[医药卫生—肿瘤]